uniQure N.V. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
uniQure closed a $259M follow-on offering (5.69M shares at $45.50/share) in June 2026, raising cash to $810.3M as of June 30, 2026 (vs. $622.5M at year-end 2025). The company expects cash to fund operations into 2030. Concurrently, AMT-130 for Huntington's disease achieved FDA alignment for BLA submission under accelerated approval in Q3 2026; U.K. regulatory submission also on track for Q3 2026. Four-year clinical data expected September 2026. Pipeline programs AMT-260 (epilepsy) and AMT-191 (Fabry disease) showed early signals but AMT-191 dosing remains paused pending liver enzyme evaluation.
Why this rating
Financing extends 4-year runway (34% of current market cap raised); regulatory alignment on lead asset AMT-130 de-risks approval path materially. Offsets elevated Q2 net loss ($81.1M vs. $37.7M YoY, driven by FX and warrant fair-value changes). Material for company trajectory.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.